Treatment for Uveitis
For noninfectious anterior uveitis, topical corticosteroids (prednisolone acetate 1%) are first-line treatment; for moderate-to-severe intermediate, posterior, or panuveitis, start with systemic disease-modifying antirheumatic drugs (methotrexate or mycophenolate mofetil) alongside corticosteroids, and escalate to adalimumab if inflammation persists or worsens. 1
Treatment Algorithm by Anatomic Location
Anterior Uveitis
- Start with topical prednisolone acetate 1% as universal first-line therapy 2
- Dosing typically begins at 6 times daily while awake 2
- Follow-up within one week to assess response 2
- If inadequate response after 2-3 weeks, switch to difluprednate drops (41% of specialists) or escalate to oral prednisone (28% of specialists) 2
Intermediate, Posterior, and Panuveitis
These subtypes carry high risk of sight-threatening complications and require systemic therapy 1
First-Line Systemic Therapy
The evidence supports starting with conventional immunosuppressants alongside corticosteroids 3, 1:
- Methotrexate: Achieves remission in 52.1% (95% CI, 38.6%-67.1%) of posterior uveitis cases 1
- Mycophenolate mofetil: Controls inflammation in 70.9% (95% CI, 57.1%-83.5%) of cases 1
- Azathioprine: Effective for inflammation control and steroid-sparing, though evidence for visual improvement is limited 3
- Calcineurin inhibitors (tacrolimus or cyclosporine): Both effective, but tacrolimus better tolerated (6% vs 37% adverse events with cyclosporine) 3
All these agents carry Grade B recommendations with Evidence Level 2B 3
Corticosteroid Management
- Target maintenance dose ≤7.5 mg prednisone daily to minimize adverse effects 4
- Initiate immunosuppression during steroid tapering 4
- For underlying systemic disease, start immunosuppression as first-line alongside steroids 4
Second-Line Biologic Therapy
Adalimumab is the biologic with strongest evidence when first-line therapy fails 1, 5:
- Extended time to treatment failure from 13 to 24 weeks vs placebo 1
- Reduced treatment failure rate from 78.5% to 54.5% (P < .001) 1
- Supported by major trials (VISUAL I, II, III in adults; SYCAMORE, ADJUVITE in children) 5
For sight-threatening Behçet's disease uveitis specifically: Infliximab may be used as first-line therapy 6
Special Considerations
Infectious Uveitis
- Requires systemic antimicrobial treatment targeting the specific pathogen 1
- Toxoplasmosis, herpes, tuberculosis, and HIV account for 11-21% of cases in high-income countries 1
- Local or systemic steroids may be added depending on severity and specific organism 1
Associated Systemic Disease
- 37-49% of uveitis cases are associated with systemic conditions like axial spondyloarthritis 1
- Requires co-management with appropriate specialist (e.g., rheumatologist) 1
Local Therapy Options
- Intravitreal corticosteroids: For patients requiring systemic therapy but unable to tolerate it 1
- Intravitreal sirolimus: Moderately effective with low adverse event risk, but evidence is limited (Grade C recommendation) 3
Critical Pitfalls to Avoid
Don't delay systemic therapy for moderate-to-severe posterior/intermediate uveitis—these patients are at high risk for irreversible vision loss 1
Don't miss infectious causes—antimicrobial therapy is fundamentally different from immunosuppression, and misdiagnosis can be catastrophic 1
Don't miss neoplastic masquerades (especially acute leukemia and retinoblastoma in children)—these can present with pseudohypopyon and inflammation mimicking uveitis 7
Don't maintain high-dose corticosteroids long-term—the goal is rapid inflammation control with steroid-sparing immunosuppression 1, 4
Individualize withdrawal decisions based on disease severity, specific uveitis cause, and risk of structural damage—premature discontinuation risks relapse 3